Clinical Trials Directory

Trials / Completed

CompletedNCT02339714

Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis

Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
98 (actual)
Sponsor
Zhao Hong · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

A multi-centre clinical trial done by us(ISRCEN90807007)showed that active acupuncture had significantly greater effect on symptoms of allergic rhinitis than either sham acupuncture or no active treatment. The object of that study was to evaluate the effectiveness and safety of acupuncture for allergic rhinitis. As an explanatory research, acupuncture was defined as the only intervention for treatment group and sham acupuncture, no active treatment as its control groups. Besides, acupuncture combined moxibustion showed better and longer effect than acupuncture on allergic rhinitis patients in our previous pilot study. According to this result, we are taking a pragmatic randomized controlled trial to further evaluate whether acupuncture combined moxibustion is more effective than conventional treatment.

Conditions

Interventions

TypeNameDescription
OTHERacupuncture combined moxibustionPoints: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether.
DRUGLoratadineLoratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.

Timeline

Start date
2015-03-01
Primary completion
2016-05-01
Completion
2018-06-01
First posted
2015-01-15
Last updated
2018-07-18

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02339714. Inclusion in this directory is not an endorsement.